SCIESCOPUSQ1
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
SAGE PUBLICATIONS INC, United Kingdom
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM is an academic journal published by SAGE PUBLICATIONS INC (United Kingdom). Identifiers: ISSN 1470-3203, eISSN 1752-8976. Indexed in SCIE, SCOPUS. Metrics: JIF 4.1, CiteScore 5.3, SJR 0.750, SNIP 0.82. Subject areas: PERIPHERAL VASCULAR DISEASE, PERIPHERAL VASCULAR DISEASES. tlooto lists 1,111 papers from this journal.
CiteScore
5.30
Scopus citation metric
SJR
0.750
SCImago rank
SNIP
0.82
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- 1470-3203
- eISSN
- 1752-8976
- Abbreviation
- J RENIN-ANGIO-ALDO S
- Publisher
- SAGE PUBLICATIONS INC
- Country
- United Kingdom
Web of Science categories
SCIEPERIPHERAL VASCULAR DISEASES
Scopus ASJC categories
1310 Endocrinology2724 Internal Medicine
Keywords
Peripheral Vascular Diseases
Papers in this journal
Recent papers
- Integrating exercise, music, and dance therapies in education to modulate the renin-angiotensin system: Implications for childhood depression
2026 · 1 citations
- Prediction of renal function improvement after percutaneous nephrolithotomy in patients with chronic kidney disease
2026
- GATM-ALDH2-Mediated mitophagy orchestrates macrophage polarization and efferocytosis to suppress AKI-to-CKD progression
2026
- The role of oxidative stress in the pathophysiology of diabetic cardiomyopathy: Crosstalk of inflammatory pathways
2026
- Interactions between AT1, AT2 and B2 receptors in the response to Ang II in the aorta of SHR rats
2026
Most cited papers
- Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension
2007 · 237 citations
- Role of Angiotensin II in Cardiovascular Disease — Therapeutic Implications of More Than a Century of Research
2006 · 236 citations
- The HOPE Study (Heart Outcomes Prevention Evaluation)
2000 · 156 citations
- The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
2000 · 146 citations
- The renin-angiotensin system meets the hallmarks of cancer
2015 · 143 citations